



Calcium-Permeable Ion Channels as Targets in Pharmacotherapy

Guest Editor:

Dr. Hussein N. Rubaiy

Department of Laboratory
Medicine, Division of Clinical
Pharmacology, Karolinska
Institute & Karolinska University
Hospital, C1:68, 141 86
Stockholm, Sweden

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Ion channels are pore-forming proteins that are involved and play essential roles in very important physiological and pathological processes; hence, they serve as therapeutic drug targets. Ca^{2+} signaling governs both millisecond-scale cellular activities, such as muscular contraction, and slower functions lasting hours or days, such as cell migration and gene transcription.

Ca^{2+} -permeable ion channels permit the influx or outflux of Ca^{2+} across the cell membrane and play a critical role in human physiology and pathology. This issue will focus on the Ca^{2+} -permeable ion channels that are responsible for the influx of extracellular Ca^{2+} , and these channels are the voltage-gated L- and T-type, TRP superfamily, ORAIs (1-3), Piezo (1, 2), and P2X receptors, which are ligand-gated ion channels.

This Special Issue aims to provide a comprehensive summary of current knowledge of the structure, regulation, function and pharmacology of Ca^{2+} -permeable ion channels in human diseases and disorders as therapeutic targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com